Laboratoire Bailly Creat

Laboratoire Bailly-Creat is a French pharmaceutical company specializing in the manufacture and distribution of generic medicines and parapharmaceutical products. Established in 1908, the company has a longstanding history in the pharmaceutical industry. It is headquartered in Vernouillet, Eure-et-Loir, France, at Chemin de Nuisement, Z.I. des 150 Arpents – B.P. 50017, 28509 Vernouillet cedex.

The company produces and distributes its products in over thirty countries, with a particular focus on markets in Africa, the Middle East, and Asia. Laboratoire Bailly-Creat is privately held and employs between 51 and 200 people. In 2021, the company reported a net revenue of €23,129,570. (journal-economique.fr)

Laboratoire Bailly-Creat's distribution network is centered around its manufacturing facility in Vernouillet, France. The company markets and distributes its products globally, with a significant presence in Africa, the Middle East, and Asia. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's extensive international reach suggests a well-established distribution infrastructure capable of supporting its global operations.

Laboratoire Bailly-Creat operates as a pharmaceutical manufacturer and distributor, focusing on the production of generic medicines and parapharmaceutical products. The company is not a wholesaler, parallel importer, hospital supplier, or logistics intermediary. Its role in France's pharmaceutical supply chain is that of a producer and exporter, supplying generic pharmaceutical products to various international markets.

Laboratoire Bailly-Creat's sourcing strategy appears to be highly concentrated, with a significant portion of its imports from India. Between 2022 and 2026, the company imported finished pharmaceutical formulations worth $909,000 USD from India, comprising 40 shipments. The top two products imported were Sulfamethoxazole and Trimethoprim, each valued at $454,000 USD, accounting for 2.3% and 1.7% of the total import value, respectively. Both products fall under the Advanced Antibiotics therapeutic category, indicating a strategic focus on this segment.

The supplier concentration is also notable, with two primary suppliers: MEDREICH LIMITED, accounting for 87.1% of the shipments, and IPCA LABORATORIES LIMITED, comprising 12.9%. This suggests a strong reliance on these suppliers for the company's antibiotic formulations. The high concentration could pose risks related to supply chain disruptions or changes in supplier dynamics. However, it may also reflect strategic partnerships aimed at ensuring consistent quality and supply.

Laboratoire Bailly-Creat's supply chain resilience concerning its Indian suppliers appears to be moderate. The company imports a diverse range of 51 unique formulations, indicating a broad product portfolio. However, the heavy reliance on two suppliers for its antibiotic formulations suggests potential vulnerabilities. The absence of backup suppliers for these critical products could expose the company to risks if any disruptions occur with MEDREICH LIMITED or IPCA LABORATORIES LIMITED. Additionally, the company's shipping routes and regulatory compliance of key suppliers are not publicly detailed, making it challenging to fully assess the resilience of the supply chain.

Laboratoire Bailly-Creat's concentrated sourcing strategy positions it as a significant player in the French market for advanced antibiotics, particularly Sulfamethoxazole and Trimethoprim. This focus allows the company to leverage economies of scale and establish strong supplier relationships. For Indian exporters, the company's reliance on a limited number of suppliers presents an opportunity to become alternative suppliers, especially if they can offer competitive pricing, consistent quality, and reliable delivery. Diversifying the supplier base could also enhance Laboratoire Bailly-Creat's supply chain resilience and reduce potential risks associated with over-reliance on a few suppliers.

In France, the primary regulatory authority overseeing pharmaceutical imports is the French National Agency for Medicines and Health Products Safety (ANSM). The ANSM is responsible for ensuring the safety, efficacy, and quality of health products available in France. Key legislation governing pharmaceutical imports includes the Public Health Code, which outlines the requirements for marketing authorization, importation, and distribution of medicinal products.

For Indian generics to be marketed in France, they must undergo a marketing authorization process, which can be obtained through the European Medicines Agency (EMA) or via national procedures. The EMA provides centralized marketing authorizations valid across all EU member states, while national procedures are specific to individual countries. The marketing authorization pathway involves rigorous evaluation of the product's quality, safety, and efficacy data.

Import licensing requirements for pharmaceutical products in France are stringent. Importers must hold a wholesale distribution authorization issued by the ANSM, which ensures compliance with Good Distribution Practice (GDP) standards. Additionally, the imported products must be manufactured in facilities that comply with Good Manufacturing Practice (GMP) standards recognized by the European Union, the World Health Organization (WHO), or the Pharmaceutical Inspection Co-operation Scheme (PIC/S). This ensures that the products meet the necessary quality standards for the French market.

Imported pharmaceutical products must undergo batch testing to confirm their quality and compliance with French and EU standards. Stability studies are required to ensure that the products maintain their efficacy and safety throughout their shelf life. Labeling requirements include providing information in French, detailing the product's composition, dosage instructions, storage conditions, and expiration date. Serialization mandates are in place to prevent counterfeit products and ensure traceability within the supply chain.

Between 2024 and 2026, several policy changes have impacted the importation of Indian pharmaceutical products into France. The ANSM has updated its guidelines to align with the EU's Falsified Medicines Directive, enhancing measures against counterfeit drugs. Additionally, there has been an increased emphasis on sustainability, with regulations encouraging the use of eco-friendly packaging and reducing carbon footprints in the supply chain. These changes aim to improve patient safety and environmental responsibility within the pharmaceutical industry.

Laboratoire Bailly-Creat's focus on advanced antibiotics, particularly Sulfamethoxazole and Trimethoprim, aligns with the ongoing demand for effective treatments against bacterial infections. The global rise in antibiotic resistance underscores the need for accessible and effective antibiotics, driving the importation of these products. By concentrating on this therapeutic area, the company positions itself to meet a critical healthcare need, ensuring a steady market demand for its products.

Laboratoire Bailly-Creat's sourcing strategy emphasizes the procurement of generic drugs, with a particular focus on antibiotic formulations. The company's reliance on Indian suppliers, such as MEDREICH LIMITED and IPCA LABORATORIES LIMITED, reflects India's strong position in the global generic pharmaceutical market. This approach allows the company to offer cost-effective products while maintaining quality standards. India's compliance with international GMP standards further supports this sourcing strategy.

Based on its product mix, Laboratoire Bailly-Creat primarily serves the wholesale distribution segment of the French market. By importing and distributing generic antibiotics, the company supplies these essential medicines to various healthcare providers, including hospitals, clinics, and pharmacies. Its focus on advanced antibiotics positions it as a key player in addressing the healthcare needs related to bacterial infections in France.

There is a realistic opportunity for new Indian suppliers to enter Laboratoire Bailly-Creat's supply chain. The company's reliance on a limited number of suppliers for its antibiotic formulations suggests potential for diversification. Indian exporters who can meet the required quality standards, offer competitive pricing, and ensure reliable delivery could establish partnerships with Laboratoire Bailly-Creat. Additionally, the company's focus on advanced antibiotics indicates a sustained demand for these products, presenting a stable market opportunity.

Indian exporters aiming to supply Laboratoire Bailly-Creat must ensure that their manufacturing facilities comply with GMP standards recognized by the EU, WHO, or PIC/S. Products must undergo batch testing and stability studies to meet French regulatory requirements. Labeling must be in French, providing comprehensive product information. Additionally, exporters should be prepared to adhere to serialization mandates to ensure product traceability and prevent counterfeiting.

To establish a relationship with Laboratoire Bailly-Creat, Indian exporters should first ensure compliance with the necessary quality standards and regulatory requirements. Engaging in direct communication with the company's procurement or business development departments is essential. Participating in international pharmaceutical trade fairs and exhibitions can provide opportunities to showcase products and network with potential partners. Understanding the company's specific needs and aligning product offerings accordingly will enhance the prospects of forming a successful partnership.